Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06462183 · ClinicalTrials.gov registry record · Phase 1

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

A Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma, sponsored by Rgenta Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
105
Enrollment target
10
Study locations

NCT06462183: Recruiting Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma, sponsored by Rgenta Therapeutics.

NCT06462183 is a Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma that is actively recruiting participants, run by Rgenta Therapeutics. The registered enrollment target is 105 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06462183, a Phase 1 study of Colorectal Cancer and Adenoid Cystic Carcinoma, is actively recruiting participants, sponsored by Rgenta Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
105 participants
Enrollment target
10
Study locations

Study Summary

Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

Interventions

  • DRUG RGT-61159

Study Locations (10)

New York

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
  • Memorial Sloan Kettering Cancer Center - New York

Ontario

  • Ottawa Hospital Cancer Centre - Ottawa
  • Princess Margaret Cancer Center - Toronto

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Michigan

  • University of Michigan - Ann Arbor

Missouri

  • Washington University School of Medicine - St Louis

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • Next Oncology VA - Fairfax

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2024-08-19
Est. Completion 2027-06
Phase Phase 1
Rgenta Therapeutics

1 total trials

What NCT06462183 shows while recruiting

NCT06462183 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (93% lower).

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which RGT-61159 is the first listed.

NCT06462183 lists 10 locations in 8 states (New York, Ontario, Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06462183 about?

NCT06462183 is a clinical study titled "Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)". Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC

What is the current status of trial NCT06462183?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2024-08-19. Estimated completion is 2027-06.

What conditions does trial NCT06462183 study?

This clinical trial studies the following conditions: Colorectal Cancer, Adenoid Cystic Carcinoma.

What interventions are being tested in trial NCT06462183?

The interventions under investigation include: RGT-61159 (DRUG).

Who is sponsoring clinical trial NCT06462183?

This trial is sponsored by Rgenta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06462183 being conducted?

This trial has 10 study locations across Massachusetts, Michigan, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06462183's enrollment target sits among peer trials

105 211th of 381 higher than 170 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06462183, the US trial registry maintained by the National Library of Medicine. NCT06462183 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.